Riax
3
Medycyna | 5.4MB
Opis
Dr.Reddy’s Laboratories Ltd. (NYSE:RDY) and AstraZeneca Pharma India Limited (AZPIL)(BSE : 506820, NSE : ASTRAZEN, AZPIL) today announced that they have entered into a distribution agreement for Riax®, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax® and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza® and Kombiglyze® for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market.
Show More
Less
Informacja
Zaktualizowano: 2015-11-08
Aktualna wersja: 1.4
Wymaga Androida: Android 3.0 or later